FDA greenlights Dupixent for children with moderate-to-severe asthma

21 October 2021
sanofi-regeneron-big

The US Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment of patients aged six to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Dupixent, which is marketed by France’s Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), generated full-year 2020 revenues of 3.5 billion euros ($4.1 billion), and 1.24 billion euros, up 57%, in the second quarter of this year, and Sanofi has an ambitious target of up to $12 billion in peak annual sales.

Asthma is one of the most common chronic diseases in children. Despite treatment with current standard-of-care inhaled corticosteroids and bronchodilators, these children may continue to experience serious symptoms such as coughing, wheezing and difficulty breathing, which could impact them through adulthood. Long-term use of systemic corticosteroids can carry significant risks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology